Newbury Pharmaceuticals AB (FRA:P52) Change In Receivables: €0.00 Mil (TTM As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P52 Newbury Pharmaceuticals AB FRA:P52
42 GF Score
Price €0.16
GF Value €0.20
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Change In Receivables?

Newbury Pharmaceuticals AB FRA:P52 -10.37% 42 Change In Receivables is €0.00 Mil as of Feb. 2026. GuruFocus rates FRA:P52 with a GF Score™ of 42/100 and a GF Value™ of €0.20. The stock has 6 warning signs investors should review.

Newbury Pharmaceuticals AB's change in receivables for the quarter that ended in Feb. 2026 was €0.00 Mil. It means Newbury Pharmaceuticals AB's Accounts Receivable stayed the same from Nov. 2025 to Feb. 2026 .

Newbury Pharmaceuticals AB's change in receivables for the fiscal year that ended in Aug. 2025 was €0.76 Mil. It means Newbury Pharmaceuticals AB's Accounts Receivable declined by €0.76 Mil from Aug. 2024 to Aug. 2025 .

Newbury Pharmaceuticals AB's Accounts Receivable for the quarter that ended in Feb. 2026 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Newbury Pharmaceuticals AB's Days Sales Outstanding for the three months ended in Feb. 2026 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Newbury Pharmaceuticals AB's liquidation value for the three months ended in Feb. 2026 was €-2.87 Mil.

Newbury Pharmaceuticals AB  (FRA:P52) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Newbury Pharmaceuticals AB's Days Sales Outstanding for the quarter that ended in Feb. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0.796*91
=0.00

2. In Ben Graham's calculation of liquidation value, Newbury Pharmaceuticals AB's accounts receivable are only considered to be worth 75% of book value:

Newbury Pharmaceuticals AB's liquidation value for the quarter that ended in Feb. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.948-4.326+0.75 * 0+0.5 * 1.023
=-2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Change In Receivables Related Terms

Newbury Pharmaceuticals AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Change In Receivables Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Change In Receivables
-0.19 0.12 -0.95 -0.62 0.76

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:P52
42GF Score
Newbury Pharmaceuticals AB FRA:P52
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.00 Mil mean?
Newbury Pharmaceuticals AB (FRA:P52) has a Change In Receivables of €0.00 Mil as of Feb. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Change In Receivables too high?
Newbury Pharmaceuticals AB's current Change In Receivables is €0.00 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Change In Receivables compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Change In Receivables of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Change In Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Change In Receivables of €0.00 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Change In Receivables is €0.00 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Change In Receivables is €0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.

Key valuation signals for FRA:P52:

  • Change In Receivables: €0.00 Mil
  • GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges NEWBRY:Sweden
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score

Get the complete analysis for FRA:P52

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.20
GF Value